No results.

Aastrom Biosciences

Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.

  1. Ixmyelocel-T: Patient-specific Multicellular Therapy

    Ixmyelocel-T is an investigational, patient-specific cell therapy in development at Aastrom for the treatment of severe, chronic cardiovascular diseases. It is derived from a patient's own bone marrow, which is collected by a physician and then processed at Aastrom. This short video explains this process and summarizes the latest clinical study of ixmyelocel-T in patients with critical limb ischemia.
    For more information, visit

  2. Living with Critical Limb Ischemia

    In this video, Rosemary and Dick Hough talk about the detrimental effects of critical limb ischemia. To learn more about CLI, visit

  3. BioMedReports Interviews Tim Mayleben, President & CEO, Aastrom Biosciences

    In this interview, Tim Mayleben offers his prospective on the potential market for ixmyelocel-T, the company's lead product candidate for critical limb ischemia and dilated cardiomyopathy.